Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-26

Study Completion Date

2019-06-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to validate the user interface of TOBI Podhaler by establishing that the product can support safe and effective use for the intended users

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031

Pseudomonas Aeruginosa in Cystic Fibrosis

COMPLETED

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

NCT00388505

Cystic Fibrosis

COMPLETED PHASE3

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

NCT00125346

Cystic Fibrosis

TERMINATED PHASE3

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397

Cystic Fibrosis

TERMINATED

A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo

NCT00918957

Cystic Fibrosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective is to conduct a human factors validation study to demonstrate that the user interface of TOBI® Podhaler™ can support safe and effective use for the intended users. The human factors validation study will be conducted in patients with cystic fibrosis aged 6 years and older under simulated yet representative of realistic use conditions where patients with no prior training or use of TOBI® Podhaler™ will be asked to inhale the contents of placebo capsules through the Podhaler device. Due to the use of placebo capsules, the study is considered an interventional clinical study and will be conducted accordingly. The study is an open label, un-blinded, non-randomized study which consists of one visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open-Label Placebo

One dose (4 capsules) of placebo

Group Type OTHER

Placebo

Intervention Type DRUG

One dose (4 capsules) of placebo

Tobi Podhaler

Intervention Type DEVICE

The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

One dose (4 capsules) of placebo

Intervention Type DRUG

Tobi Podhaler

The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent or, parent/guardian consent and where applicable pediatric assent, must be obtained before any assessment is performed
* Male and female subjects aged 6 years and older
* Confirmed diagnosis of CF by one or more of the following tests for CF as documented in the patient's medical history : (1) quantitative pilocarpine iontophoresis sweat chloride test of \> 60 mmol/L or 60 mEq/L, (2) genotype with identifiable CF-causing mutations on both chromosomes, (3) an abnormal nasal transepithelial potential difference characteristic of CF
* FEV1 value must be at least 25% of normal predicted values for age, sex, and height as documented in the patient's medical history (historical values within 3 months can be used for this criterion).
* Able to comply with all protocol requirements
* Clinically stable in the opinion of the investigator

Exclusion Criteria

* Subjects currently enrolled in studies that are not considered as observational non-investigational studies
* Subjects or caregivers who have used the Podhaler device previously
* Hemoptysis more than approximately 60 mL at any time within 30 days prior to enrollment
* History of hypersensitivity to the inhaled placebo dry powder (DSPC and/or calcium chloride powder)
* Signs and symptoms of acute pulmonary disease, e.g. pneumonia, pneumothorax, bronchospasm, acute respiratory infection
* Clinically significant conditions or findings at enrollment that might interfere with the accurate and valid assessment of this study
* Subjects or caregivers who are considered potentially unreliable or considered unlikely to be compliant within the trial
* Pregnant women

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No